These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 11602636)

  • 1. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
    Aladin F; Lautscham G; Humphries E; Coulson J; Blake N
    Cancer Immunol Immunother; 2007 Aug; 56(8):1143-52. PubMed ID: 17143611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
    Khanna R; Burrows SR; Moss DJ; Silins SL
    J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
    Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
    Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28.
    van Hall T ; Sijts A; Camps M; Offringa R; Melief C; Kloetzel PM; Ossendorp F
    J Exp Med; 2000 Aug; 192(4):483-94. PubMed ID: 10952718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.
    Lautscham G; Haigh T; Mayrhofer S; Taylor G; Croom-Carter D; Leese A; Gadola S; Cerundolo V; Rickinson A; Blake N
    J Virol; 2003 Feb; 77(4):2757-61. PubMed ID: 12552018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
    López D; Gil-Torregrosa BC; Bergmann C; Del Val M
    J Immunol; 2000 May; 164(10):5070-7. PubMed ID: 10799863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.
    Kuzushima K; Hayashi N; Kudoh A; Akatsuka Y; Tsujimura K; Morishima Y; Tsurumi T
    Blood; 2003 Feb; 101(4):1460-8. PubMed ID: 12393434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
    Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of TAP-independent and brefeldin A-resistant presentation of Sendai virus antigen to CD8+ cytotoxic T lymphocytes.
    Zhou X; Liu T; Franksson L; Lederer E; Ljunggren HG; Jondal M
    Scand J Immunol; 1995 Jul; 42(1):66-75. PubMed ID: 7631147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.
    Lucchiari-Hartz M; van Endert PM; Lauvau G; Maier R; Meyerhans A; Mann D; Eichmann K; Niedermann G
    J Exp Med; 2000 Jan; 191(2):239-52. PubMed ID: 10637269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus.
    Lautscham G; Rickinson A; Blake N
    Microbes Infect; 2003 Apr; 5(4):291-9. PubMed ID: 12706442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.
    Luckey CJ; King GM; Marto JA; Venketeswaran S; Maier BF; Crotzer VL; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH
    J Immunol; 1998 Jul; 161(1):112-21. PubMed ID: 9647214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
    Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
    Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.